Relinquish-M Tablet (Artemisinin 62.50mg + Piperaquine 375mg)

SKU: N/A
In Stock

$70.00$249.00

Tablet PriceQuantity
80 Tablet/s $70.00
160 Tablet/s $130.00
320 Tablet/s $249.00

Description

Relinquish-M Tablet is a pharmaceutical tablet commonly prescribed to manage and treat specific medical conditions. The tablet generally contains two primary active ingredients: Metformin and Vildagliptin. These are combined to provide a synergistic effect in managing type 2 diabetes mellitus, a chronic condition characterized by elevated blood sugar levels.

Key Ingredients and Their Functions

  1. Metformin:
    • Function: Metformin is a biguanide-class drug. It primarily decreases hepatic glucose production, reduces the intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
    • Mechanism of Action: Metformin activates AMP-activated protein kinase (AMPK), an enzyme that plays a critical role in cellular energy homeostasis. By doing so, it inhibits gluconeogenesis in the liver, which results in lower blood glucose levels.
    • Benefits: It helps control high blood sugar, preventing kidney damage, blindness, nerve problems, and loss of limbs. It may also reduce the risk of heart attack or stroke.
  2. Vildagliptin:
    • Function: Vildagliptin belongs to the DPP-4 (dipeptidyl peptidase-4) inhibitor class. It works by increasing the levels of incretin hormones, which help to regulate glucose by increasing insulin synthesis and release from the pancreatic beta cells in a glucose-dependent manner.
    • Mechanism of Action: By inhibiting DPP-4, Vildagliptin increases the amount of active incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion and lowering glucagon levels, which helps to regulate blood glucose levels more effectively.
    • Benefits: Vildagliptin is effective in improving glycemic control, and reducing postprandial glucose excursions, and is generally well-tolerated with a low risk of hypoglycemia.

If you need to buy Quinine Sulphate 300mg you can purchase now our Generic Cure medicine.

Uses of Relinquish-M Tablet

  • Type 2 Diabetes Management: The primary use of Relinquish-M tablets is to manage type 2 diabetes mellitus in adults, particularly when diet, exercise, and single-drug therapy do not provide adequate glycemic control.
  • Glycemic Control: The combination of Metformin and Vildagliptin in Relinquish-M offers a comprehensive approach to controlling blood glucose levels throughout the day, including after meals.
  • Combination Therapy: Relinquish-M can be used in combination with other antidiabetic agents when monotherapy does not provide sufficient control.

Relinquish-M Tablet Dosage and Administration

  • Standard Dosage: The dosage of Relinquish-M typically depends on the patient’s current health condition, blood glucose levels, and response to treatment. It is commonly prescribed as one tablet taken once or twice daily, with or after meals to reduce gastrointestinal side effects.
  • Adjustment: Dose adjustments may be necessary based on the patient’s renal function, as Metformin is excreted unchanged by the kidneys. Regular monitoring of kidney function is recommended.
  • Adherence: Patients are advised to take Relinquish-M regularly and at the same time each day to maintain stable blood levels of the medication.

What are the Side Effects of Relinquish-M Tablet?

  1. Common Side Effects:
    • Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort are relatively common with Metformin.
    • Headache and dizziness may occur with Vildagliptin.
  2. Serious Side Effects:
    • Lactic Acidosis: A rare but serious side effect associated with Metformin, particularly in patients with kidney impairment. Symptoms include muscle pain, respiratory distress, and abdominal discomfort. Immediate medical attention is required if these symptoms appear.
    • Pancreatitis: Vildagliptin has been associated with a risk of pancreatitis. Patients should seek medical attention if they experience severe abdominal pain that may radiate to the back, along with nausea and vomiting.
    • Hypoglycemia: While Vildagliptin itself has a low risk of causing hypoglycemia, the risk increases when combined with other antidiabetic drugs such as sulfonylureas or insulin.
  3. Allergic Reactions: Some patients may experience allergic reactions, including rash, itching, swelling, severe dizziness, or trouble breathing.

Precautions and Warnings

  • Kidney Function: Since Metformin is excreted through the kidneys, patients with impaired kidney function must use Relinquish-M with caution. Regular kidney function tests are recommended.
  • Liver Function: Vildagliptin should be used cautiously in patients with liver impairment. Liver function tests should be performed before starting therapy and periodically thereafter.
  • Heart Conditions: Patients with a history of heart disease should inform their doctor before starting Relinquish-M, as the medication may influence heart function.
  • Pregnancy and Breastfeeding: Relinquish-M is not typically recommended for use during pregnancy or breastfeeding. Women of childbearing age should discuss effective contraception methods with their healthcare provider while on this medication.
  • Alcohol Use: Patients are advised to limit or avoid alcohol consumption while taking Relinquish-M, as alcohol can increase the risk of lactic acidosis and negatively affect blood sugar control.

Drug Interactions

  • Other Antidiabetic Drugs: The use of Relinquish-M alongside other antidiabetic drugs may increase the risk of hypoglycemia. Close monitoring of blood glucose levels is necessary.
  • Diuretics: Some diuretics can increase blood sugar levels and may reduce the efficacy of Relinquish-M.
  • ACE Inhibitors: The combination with ACE inhibitors may enhance the glucose-lowering effect of Relinquish-M, necessitating dosage adjustments.
  • Corticosteroids: These may counteract the effects of Relinquish-M by increasing blood glucose levels.

Storage and Handling

  • Storage Conditions: Relinquish-M tablets should be stored at room temperature, away from direct sunlight and moisture. It should be kept out of reach of children and pets.
  • Handling: Patients should ensure that the tablets are stored in their original packaging until they are ready to use them, to protect them from moisture and contamination.

Other Pills:

Artemisinin 100 mg, Hydroxychloroquine 200 mg, HCQS 400 Mg Tablets, HCQS 200 Mg Tablets, Plaquenil 200 mg

Additional information

Tablet

80 Tablet/s, 160 Tablet/s, 320 Tablet/s

Active Ingredient (Generic Name)

Artemisinin/Piperaquine

Indication

Malaria

Manufacturer

Kachhela Medex Private Limited

Packaging

4 Tablet in 1 strip

Delivery Time

6 To 15 days